% | $
Quotes you view appear here for quick access.

Northwest Biotherapeutics, Inc. Message Board

  • annickawaechter annickawaechter Sep 24, 2013 11:36 AM Flag

    $10,33/share target based on the potential of DCVax-L

    UK priority trial
    Fraunhofer cooperation
    5.5 million dollar German government grant
    Cleveland clinic, Kings College, ...
    55 clinical sites in the US
    Compassionate use programm in the UK
    two patients from phase I are still alive after for more than 10 years

    1st interim analysis from the FDA data monitoring board before the end of this years for efficacy and safety, and possible BLA grantuition

    this is where I place my money and where Summer Street Research places a 10,33 dollar/share target

    MD Anderson I en II are now both in DCvax-direct... Do you honestly think that the second site of MD Anderson would participate if the results weren't promissing? Do you honestly think they would do that and make a fool of themselves and ruin their excellent reputation somehow?

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I think you are correct. Lately, I spend some of my time studying the clinics/sponsors' viewpoints on drugs they ask or are asked to test. MD Anderson, despite their willingness to try new treatments, is very aware and cautious regarding first and second phase trials. What one of our poster's recalled, in his conversation with Les, sounds correct -- namely, MD Anderson is not "expecting" 80-100 percent efficacy with direct. Based upon their prior experience with other companies, they expect something more on the order of 30%. That being said, they would certainly be thrilled with 80 to 100% if it panned out. I have a filling if our poster correctly recalled his conversation with Les, that Les heard this prediction by MD Anderson before the first dose was given.

      Of course a 30% cure rate would be phenomenal. The world is simply hoping it is higher.

      I think you mean 10.33 not 10,33.

      • 2 Replies to mtaotter
      • nowwhat, I don't think NWBO is sunk if DCVax-Direct isn't a success. True, it will mean that it will take longer for NWBO to create some space from the pack. But summarizing the points others have made: DCVax-L (1) is a vaccine for many different forms of cancer; (2) is in phase 3; (3) will be approved in both the EU and US if successful; and (4) has its own manufacturing process in place. There will be a place for it once approved, regardless of the competition. They should be worried about NWBO.

        But let's hope it's a non-issue on what will happen if DCVax-Direct disappoints. I prefer to think about the potential for it to send NWBO's price skyward when results show that it works. I thought today's PR was quite bullish. I definitely think the early results had to have been good or Anderson wouldn't have agreed to expand the trial to another site. Ditto on Europe. Evidently Wall Street chose to focus on the fact that results are still a few months off.

        Otter, in Europe they use a comma where we use a decimal.

        Sentiment: Buy

      • "feeling" Not sure if that was typo plus spell check, or just me.

7.72+0.11(+1.45%)Sep 4 4:00 PMEDT